Logo

SpeeDx, GSK Sign Test Supply, Development Deal

Jun 24, 2019 | staff reporter

NEW YORK (GenomeWeb) – SpeeDx said today that it has entered a test development collaboration with British drugmaker GlaxoSmithKline.

According to Sydney-based SpeeDx, it will provide GSK with a combination of existing and custom-developed molecular diagnostic tests to support its antibiotic clinical trials, as well as its new product development efforts.

Additional terms were not disclosed.

"We welcome this extension of the utility and application of our tests and technology," SpeeDx CEO Colin Denver said in a statement. "Our tests currently used in clinical practice are supporting resistance guided therapy, positively impacting cure rates and helping to minimize the spread of antimicrobial resistant infections."

Filed under

Molecular Diagnostics
Infectious Disease
PCR
Drug Discovery & Development
Business News
Asia/Oceania
Europe
GSK
SpeeDx
Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.